Can-Fite BioPharma Ltd. announced the granting of a patent in Brazil for the treatment of sexual dysfunction using their A3 adenosine receptor agonists. This provides protection in a key pharmaceutical market in Latin America. The company’s research suggests that activating the A3 adenosine receptor can impact erectile and sexual function. This patent expands Can-Fite’s global intellectual-property portfolio, creating potential opportunities for future partnerships and commercialization in Latin America. The company is also advancing its A3AR agonist platform for various conditions, including oncology and inflammatory diseases.

Can-Fite BioPharma Ltd. is a biotechnology company with a focus on developing drugs for cancer, liver, and inflammatory diseases. They have multiple drug candidates in clinical trials, including Piclidenoson for psoriasis and Namodenoson for hepatocellular carcinoma. Can-Fite’s drugs have shown efficacy in treating conditions like erectile dysfunction and have a strong safety profile. The company is actively seeking strategic opportunities to maximize the value of its patent estate. Investors are urged to consider the risks and uncertainties associated with forward-looking statements in the biopharmaceutical industry.

Read more at GlobeNewswire: Can-Fite Granted Brazilian Patent for Treatment of Sexual